AlloVir, Inc. logo

AlloVir, Inc.

NASDAQ:ALVR

Overview | Financials
Company Name AlloVir, Inc.
Symbol ALVR
Currency USD
Price 9.81
Market Cap 49,475,362
Dividend Yield 0%
52-week-range 7.96 - 24.15
Industry Biotechnology
Sector Healthcare
CEO Dr. Diana M. Brainard M.D.
Website https://www.allovir.com

An error occurred while fetching data.

About AlloVir, Inc.

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus

Related Stocks

Lexicon Pharmaceuticals, Inc. logo

Lexicon Pharmaceuticals, Inc.

LXRX

0.689 USD

Dyne Therapeutics, Inc. logo

Dyne Therapeutics, Inc.

DYN

11.295 USD

4D Molecular Therapeutics, Inc. logo

4D Molecular Therapeutics, Inc.

FDMT

3.24 USD

ClearPoint Neuro, Inc. logo

ClearPoint Neuro, Inc.

CLPT

14.25 USD

Ocular Therapeutix, Inc. logo

Ocular Therapeutix, Inc.

OCUL

7.45 USD

Theratechnologies Inc. logo

Theratechnologies Inc.

THTX

2.74 USD

Financials

Numbers are in millions USD

Numbers are in millions USD